Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDAC2 | P45880 | 1/20 | 0.62 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27256091 | 0.91 | SLC7A11 (0.73) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL13998015 | 0.83 | SLC7A11 (0.79) | VDAC2SLC7A11KCNH2HRH3KMT2A | |
| SCHEMBL13633591 | 0.83 | SLC7A11 (0.64) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL13633614 | 0.81 | VDAC2 (0.57) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL13633653 | 0.81 | VDAC2 (0.60) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL12659722 | 0.80 | MAPT (0.61) | KCNH2HRH3CXCR3KMT2AMAPT | |
| SCHEMBL27256099 | 0.80 | VDAC2 (0.55) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL13633731 | 0.79 | SLC7A11 (0.64) | VDAC2SLC7A11KCNH2HRH3CXCR3 | |
| SCHEMBL13633718 | 0.79 | SLC7A11 (0.89) | VDAC2SLC7A11LMNAALDH1A1 | |
| SCHEMBL4462685 | 0.79 | VDAC2 (0.73) | VDAC2SLC7A11KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | VDAC2 1593/4885SLC7A11 452/4885KCNH2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.